Drug intelligence / Profile preview

NPH insulin + inhaled human insulin

Development stage
Discontinued
Lead developer
Mannkind
Administration
Subcutaneous, Inhalation
01

Overview

The combination of NPH insulin and inhaled human insulin represents a treatment approach for diabetes mellitus that pairs an intermediate-acting injectable insulin with a rapid-acting inhaled insulin formulation.\n\nNPH insulin (Neutral Protamine Hagedorn) serves as the basal insulin component, providing background insulin coverage for 12-18 hours. It typically peaks at 4-12 hours after injection and helps control blood glucose between meals and overnight[4].\n\nThe inhaled human insulin component (brand name Afrezza, formerly Exubera) is a dry powder form of rapid-acting insulin delivered by oral inhalation[2]. It starts working within 10-15 minutes, peaks at 35-45 minutes, and has a duration of 1.5-3 hours[4]. This rapid action makes it suitable for controlling mealtime blood glucose spikes.\n\n## Clinical Evidence\n\nClinical trials have demonstrated that this combination can provide effective glycemic control. In patients with type 1 diabetes, studies showed that inhaled insulin before meals plus ultralente insulin at night provided comparable glycemic control to conventional insulin regimens[3]. Similarly, in type 2 diabetes, the combination of inhaled insulin with basal insulin has shown effectiveness in controlling blood glucose levels[5].\n\n## Administration\n\nThe NPH insulin is administered subcutaneously, typically once or twice daily. The inhaled insulin is administered at the beginning of meals using a specialized inhaler device[1]. This combination reduces, but does not eliminate, the need for injections in patients with diabetes.\n\n## Safety Considerations\n\nCommon side effects of inhaled insulin include hypoglycemia, cough, throat pain, and potential decreases in pulmonary function[2][6]. Pulmonary function should be monitored during treatment, with baseline spirometry followed by repeat testing at six months and one year, with yearly follow-up thereafter[2]. Inhaled insulin is contraindicated in patients with chronic pulmonary diseases such as asthma and COPD[5].

Brand names
Exubera
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on NPH insulin + inhaled human insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPH insulin + inhaled human insulin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call